Notes: MEGX is an active metabolite of lidocaine.{42862} It is formed via N-deethylation of lidocaine by the hepatic cytochrome P450 (CYP) isoform CYP3A4. Topical administration of MEGX (2% v/v) reduces thrombus formation in a hamster model of laser-induced microvascular injury.{42863} Plasma levels of MEGX following lidocaine administration have been used to monitor declining liver function in patients with cirrhosis.{42862}